Previous close | 5.76 |
Open | 5.73 |
Bid | 6.01 x 900 |
Ask | 6.02 x 1400 |
Day's range | 5.71 - 6.13 |
52-week range | 5.61 - 82.30 |
Volume | |
Avg. volume | 6,775,821 |
Market cap | 520.486M |
Beta (5Y monthly) | 1.78 |
PE ratio (TTM) | N/A |
EPS (TTM) | -8.50 |
Earnings date | 08 May 2023 - 12 May 2023 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 50.80 |
In the latest trading session, Novavax (NVAX) closed at $5.76, marking a -0.35% move from the previous day.
The departing party is Greg Glenn, the president of research and development. First, research and development is a crucial area for biotechs like Novavax, as their future is heavily dependent on their pipeline programs. Second, Glenn was a longtime company mainstay, having joined Novavax in 2010.
Novavax (NASDAQ: NVAX) has had more than its share of ups and downs over the past few years -- and investors have been along for the ride. The stock soared 2,700% in 2020 as the company brought its coronavirus vaccine candidate through late-stage clinical trials. The biotech company's vaccine reached commercialization later than rivals.